Reuters logo
BRIEF-‍Novartis' Rydapt Approved Following Priority Review By Health Canada​
December 5, 2017 / 11:10 AM / 12 days ago

BRIEF-‍Novartis' Rydapt Approved Following Priority Review By Health Canada​

Dec 5 (Reuters) - Novartis Ag:

* ‍NOVARTIS PHARMACEUTICALS CANADA - RYDAPT (MIDOSTAURIN) HAS BEEN APPROVED FOLLOWING A PRIORITY REVIEW BY HEALTH CANADA​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below